What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?
Are there certain patient subgroups for whom you would use the IO+PARPi?
Is there data from DUO-E regarding BRCA status and its potential impact on outcomes?
Community PollStarted
Do you plan to incorporate a PARP inhibitor into the management of patients receiving chemo+IO for advanced/recurrent endometrial cancer?
57 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Gynecologic Oncology · Alliance Cancer Specialists, PC
Answered on
The results of DUO-E are very exciting and will serve a number of purposes. I was encouraged to continue to see that the combo of chemo IO performed better than chemo alone confirming the class effect that was seen in GY018 and RUBY. I wish there was a pre-planned comparison of the chemo/IO/Olaparib...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Gynecologic Oncology · UCLA David Geffen School of Medicine/UCLA Medical Center
Answered on
Based on the results of the primary objectives of DUO-E, I would only consider chemo+durva+olaparib in the pMMR patient however, I do not truly know the benefit of adding olaparib to IO in this patient population. I would like to see trials designed to compare chemo+IO versus chemo+IO+olaparib in th...
Join for free or sign in to see the full answer